Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.64 |
| ▸ | DRD3 | P35462 | 2/20 | 0.64 |
| ▸ | HTR2B | P41595 | 2/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.64 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 7/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7292336 | 0.99 | LMNA (0.65) | CYP3A4CYP2D6TSHRADRB1ADRA2A | |
| Acetic Acid SCHEMBL7282924 | 0.97 | TSHR (0.61) | CYP3A4CYP2D6TSHRADRB1ADRA2A | |
| SCHEMBL7282505 | 0.93 | TSHR (0.59) | CYP3A4CYP2D6TSHRADRB1ADRA2A | |
| SCHEMBL7281889 | 0.92 | CYP3A4 (0.57) | CYP3A4CYP2D6TSHRADRB1ADRA2A | |
| SCHEMBL7291787 | 0.91 | LMNA (0.57) | CYP3A4CYP2D6TSHRADRB1ADRA2A | |
| SCHEMBL7283258 | 0.89 | ABCB1 (0.68) | TSHRLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7291944 | 0.89 | TSHR (0.56) | CYP3A4CYP2D6TSHRADRB1ADRA2A | |
| SCHEMBL7282171 | 0.89 | KMT2A (0.59) | CYP3A4CYP2D6TSHRADRB1ADRA2A | |
| SCHEMBL7281734 | 0.88 | CYP2D6 (0.58) | CYP2D6TSHRMEN1KMT2AABCB1 | |
| SCHEMBL7283526 | 0.87 | L3MBTL1 (0.60) | CYP2D6TSHRLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008047388-A2 | IMPROVED PROCESS FOR THE PREPARATION OF RANOLAZINE | IND-SWIFT LABORATORIES LIMITED (IN) | 2008-04-24 | — | — | WO | claimed |
| US-4567264-A | ADRENERGIC BLOCKING AGENTS | SYNTEX (U.S.A.) INC. (US) | 1986-01-28 | — | — | US | claimed |
| EP-0126449-A1 | Cardioselective aryloxy- and arylthio-hydroxypropyl piperazinyl acetanilides wich affect calcium entry | SYNTEX (U.S.A.) INC. (US) | 1984-11-28 | — | — | EP | claimed |
| EP-2861254-A2 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | Acesion Pharma ApS (DK) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013185764-A2 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | ACESION PHARMA (DK) | 2013-12-19 | — | — | WO | disclosed |
| EP-2480234-A2 | SUSTAINED RELEASE COMPOSITION OF RANOLAZINE | Lupin Limited (IN) | 2012-08-01 | — | — | EP | disclosed |
| EP-2429526-A1 | RANOLAZINE FOR THE TREATMENT OF CNS DISORDERS | Gilead Sciences, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20120046299-A1 | METHOD OF TREATING ARRHYTHMIAS | GILEAD SCIENCES, INC. | 2012-02-23 | — | — | US | disclosed |
| US-7943620-B2 | Anti-anginal compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2139877-B1 | DEUTERATED PIPERAZINE DERIVATIVES AS ANTI-ANGINAL COMPOUNDS | CONCERT PHARMACEUTICALS INC (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2011036677-A2 | SUSTAINED RELEASE COMPOSITION OF RANOLAZINE | LUPIN LIMITED (IN) | 2011-03-31 | — | — | WO | disclosed |
| EP-0714660-B1 | Ranolazine and related piperazines for protecting skeletal muscles | SYNTEX LLC (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-0719558-B1 | Ranolazine and related piperazines for use in the treatment of shock conditions | SYNTEX LLC (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-0407780-B1 | Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult | SYNTEX INC (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0719558-A1 | Ranolazine and related piperazines for use in the treatment of shock conditions | SYNTEX PHARMACEUTICALS LTD. (GB) | 1996-07-03 | — | — | EP | disclosed |
| EP-0714660-A1 | Ranolazine and related piperazines for protecting skeletal muscles | SYNTEX PHARMACEUTICALS LTD. (GB) | 1996-06-05 | — | — | EP | disclosed |
| US-5506229-A | SKELETAL AND MUSCLE DISORDERS | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1996-04-09 | — | — | US | disclosed |
| EP-0407780-A2 | Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult | SYNTEX PHARMACEUTICALS LTD. (GB) | 1991-01-16 | — | — | EP | disclosed |
| US-4567264-A | ADRENERGIC BLOCKING AGENTS | SYNTEX (U.S.A.) INC. (US) | 1986-01-28 | — | — | US | disclosed |
| EP-0126449-A1 | Cardioselective aryloxy- and arylthio-hydroxypropyl piperazinyl acetanilides wich affect calcium entry | SYNTEX (U.S.A.) INC. (US) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046299-A1 | METHOD OF TREATING ARRHYTHMIAS | TNNI3, TNNT2, TTN | CYP3A4 827/4885CYP2D6 551/4885TSHR 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.